US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.49 against a street estimate of 0.70 — a miss of 170.0%.
Analysts rate Liquidia Technologies Inc a buy (4 buy, 4 hold, 0 sell out of 8) with an average price target of $54.38.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.05% |
| Farallon Capital Management, L.L.C. | 9.35% |
| Caligan Partners LP | 9.07% |
| Findell Capital Management LLC | 3.91% |
| Vanguard Capital Management, LLC | 3.51% |
| State Street Corp | 3.39% |
| Opaleye Management Inc | 2.73% |
| Geode Capital Management, LLC | 2.37% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • Liquidia reached a settlement with United Therapeutics Corporation (UTC) covering all ongoing litigation, including patent, trade- | 2026-10-14 |
| Company announcement · Q3 2026 HEADLINE NUMBERS • Liquidia Corporation filed a Form 8-K on September 30, 2026. • The filing concerns litigation involving United Therapeutics Corpo | 2026-09-30 |
| Company announcement · Q3 2026 LIQUIDIA CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Liquidia Corporation (ticker: LQDA, Nasdaq-listed) • Report date: September 3, 2 | 2026-09-03 |
| Quarterly report · Q2 2026 LIQUIDIA CORPORATION - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and cash equivalents: $284.2 million as of Jun | 2026-08-12 |
| Results announced · Q3 2026 LIQUIDIA CORPORATION Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 YUTREPIA net product sales: $170.4 million, up 31% from Q1 2026 ($ | 2026-08-12 |
| Shareholder vote results · Q2 2026 LIQUIDIA CORPORATION (LQDA) - 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 16, 2026 • 88,893,621 shares outstanding as of Apr | 2026-06-17 |
| Company announcement · Q2 2026 LIQUIDIA CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Liquidia Corporation (NASDAQ: LQDA) • Headquarters: 419 Davis Drive, Suite 100, | 2026-06-08 |
| Quarterly report · Q1 2026 LIQUIDIA CORPORATION – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and Cash Equivalents: $222.8 million as of March 31, 2026 (up fr | 2026-05-11 |
Readable in the app.
| Announcement | Date |
|---|---|
| Exclusive licensing agreement for treprostinil product development and commercialization Liquidia Corporation signed an exclusive licensing deal with Vectura Limited on October 27, 2025, to develop and sell treprostinil-based treatments in the U.S. market. The drug will be admin | 2025-10-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Liquidia Technologies Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.